The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo

Mitra Sehi, Dilraj S. Grewal, William J Feuer, David Greenfield

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005% versus placebo. Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00. am and 4:00. pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4. weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis. Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6. years) were enrolled. The mean IOP (mm. Hg) after latanoprost 0.005% therapy (14.9 ± 3.8) was significantly lower than baseline (18.8 ± 4.7, p<0.001) or placebo (18.0 ± 4.3), with a mean reduction of -20 ± 13%. Mean PERGLA amplitude (μV) and phase (π-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were similar (p>0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24 and 1.72 ± 0.23). No significant (p>0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p>0.05) associated with PERGLA amplitude or phase. Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalVision Research
Volume51
Issue number2
DOIs
StatePublished - Jan 28 2011

Fingerprint

latanoprost
Retinal Ganglion Cells
Intraocular Pressure
Glaucoma
Placebos
Ocular Hypertension
Complementary Therapies
Cross-Over Studies
Clinical Trials

Keywords

  • Glaucoma
  • Intraocular pressure
  • Latanoprost
  • Pattern electroretinogram
  • Retinal ganglion cell

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo. / Sehi, Mitra; Grewal, Dilraj S.; Feuer, William J; Greenfield, David.

In: Vision Research, Vol. 51, No. 2, 28.01.2011, p. 235-242.

Research output: Contribution to journalArticle

@article{81351281d2fa468b967c862fc9aaab12,
title = "The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005{\%} versus placebo",
abstract = "Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005{\%} versus placebo. Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00. am and 4:00. pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4. weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis. Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6. years) were enrolled. The mean IOP (mm. Hg) after latanoprost 0.005{\%} therapy (14.9 ± 3.8) was significantly lower than baseline (18.8 ± 4.7, p<0.001) or placebo (18.0 ± 4.3), with a mean reduction of -20 ± 13{\%}. Mean PERGLA amplitude (μV) and phase (π-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were similar (p>0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24 and 1.72 ± 0.23). No significant (p>0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p>0.05) associated with PERGLA amplitude or phase. Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.",
keywords = "Glaucoma, Intraocular pressure, Latanoprost, Pattern electroretinogram, Retinal ganglion cell",
author = "Mitra Sehi and Grewal, {Dilraj S.} and Feuer, {William J} and David Greenfield",
year = "2011",
month = "1",
day = "28",
doi = "10.1016/j.visres.2010.08.036",
language = "English",
volume = "51",
pages = "235--242",
journal = "Vision Research",
issn = "0042-6989",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo

AU - Sehi, Mitra

AU - Grewal, Dilraj S.

AU - Feuer, William J

AU - Greenfield, David

PY - 2011/1/28

Y1 - 2011/1/28

N2 - Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005% versus placebo. Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00. am and 4:00. pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4. weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis. Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6. years) were enrolled. The mean IOP (mm. Hg) after latanoprost 0.005% therapy (14.9 ± 3.8) was significantly lower than baseline (18.8 ± 4.7, p<0.001) or placebo (18.0 ± 4.3), with a mean reduction of -20 ± 13%. Mean PERGLA amplitude (μV) and phase (π-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were similar (p>0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24 and 1.72 ± 0.23). No significant (p>0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p>0.05) associated with PERGLA amplitude or phase. Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.

AB - Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005% versus placebo. Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00. am and 4:00. pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4. weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis. Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6. years) were enrolled. The mean IOP (mm. Hg) after latanoprost 0.005% therapy (14.9 ± 3.8) was significantly lower than baseline (18.8 ± 4.7, p<0.001) or placebo (18.0 ± 4.3), with a mean reduction of -20 ± 13%. Mean PERGLA amplitude (μV) and phase (π-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were similar (p>0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24 and 1.72 ± 0.23). No significant (p>0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p>0.05) associated with PERGLA amplitude or phase. Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost

KW - Pattern electroretinogram

KW - Retinal ganglion cell

UR - http://www.scopus.com/inward/record.url?scp=78651507938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651507938&partnerID=8YFLogxK

U2 - 10.1016/j.visres.2010.08.036

DO - 10.1016/j.visres.2010.08.036

M3 - Article

C2 - 20813123

AN - SCOPUS:78651507938

VL - 51

SP - 235

EP - 242

JO - Vision Research

JF - Vision Research

SN - 0042-6989

IS - 2

ER -